Premium
The use of plerixafor in harvesting autologous stem cells in the pediatric setting
Author(s) -
Vettenranta Kim,
Möttönen Merja,
Riikonen Pekka
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23361
Subject(s) - plerixafor , medicine , blood cancer , chemotherapy , stem cell , pediatric oncology , oncology , surgery , cancer , cxcr4 , chemokine , receptor , biology , genetics
Abstract The mobilization of stem cells using the standard approach, chemotherapy and G‐CSF, may not be successful in all cases heavily pretreated. Plerixafor (AMD3100) has emerged as a viable option in attempts to mobilize stem cells among these patients. The use of plerixafor in the adult setting has been established, but data on pediatric use is scarce. We report on the use of plerixafor in eight pediatric cases either as add‐on to chemotherapy plus G‐CSF or in remobilization. Pediatr Blood Cancer 2012; 59: 197–198. © 2011 Wiley Periodicals, Inc.